Barak Investment House Past Earnings Performance
Past criteria checks 0/6
Barak Investment House has been growing earnings at an average annual rate of 7.5%, while the Pharmaceuticals industry saw earnings growing at 11% annually. Revenues have been growing at an average rate of 14.2% per year.
Key information
7.5%
Earnings growth rate
18.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 35.1% |
| Revenue growth rate | 14.2% |
| Return on equity | n/a |
| Net Margin | -68.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses Breakdown
How Barak Investment House makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 20 | -13 | 13 | 0 |
| 30 Sep 23 | 20 | -22 | 13 | 0 |
| 30 Jun 23 | 26 | -30 | 15 | 0 |
| 31 Mar 23 | 33 | -37 | 16 | 0 |
| 31 Dec 22 | 39 | -43 | 17 | 0 |
| 30 Sep 22 | 58 | -41 | 25 | 0 |
| 30 Jun 22 | 70 | -34 | 29 | 0 |
| 31 Mar 22 | 76 | -22 | 32 | 0 |
| 31 Dec 21 | 84 | -21 | 35 | 0 |
| 30 Sep 21 | 77 | -20 | 36 | 0 |
| 30 Jun 21 | 71 | -22 | 38 | 0 |
| 31 Mar 21 | 68 | -35 | 39 | 0 |
| 31 Dec 20 | 61 | -36 | 40 | 0 |
| 30 Sep 20 | 50 | -90 | 49 | 0 |
| 30 Jun 20 | 38 | -85 | 42 | 0 |
| 31 Mar 20 | 26 | -80 | 35 | 0 |
| 31 Dec 19 | 17 | -81 | 27 | 0 |
| 30 Sep 19 | 12 | -19 | 9 | 0 |
| 30 Jun 19 | 9 | -18 | 7 | 0 |
| 31 Mar 19 | 6 | -16 | 6 | 0 |
| 31 Dec 18 | 4 | -7 | 5 | 0 |
| 31 Dec 17 | 0 | -2 | 1 | 0 |
Quality Earnings: BARI is currently unprofitable.
Growing Profit Margin: BARI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BARI is unprofitable, but has reduced losses over the past 5 years at a rate of 7.5% per year.
Accelerating Growth: Unable to compare BARI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BARI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (6.8%).
Return on Equity
High ROE: BARI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.